STOCK TITAN
  1. Home
  2. News
  3. TNXP

Tonix Pharmaceuticals Holding Corp - TNXP STOCK NEWS

Welcome to our dedicated news page for Tonix Pharmaceuticals Holding (Ticker: TNXP), a resource for investors and traders seeking the latest updates and insights on Tonix Pharmaceuticals Holding.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tonix Pharmaceuticals Holding's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tonix Pharmaceuticals Holding's position in the market.

News
Tonix Pharmaceuticals Announces Presentation at Planet MicroCap Showcase
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announced that Dr. Seth Lederman will present at the Planet MicroCap Showcase to discuss positive Phase 3 trial data of Tonmya for fibromyalgia management. The company focuses on CNS disorders and plans to submit an NDA for Tonmya in 2024. Tonix also works on biologics for organ transplant rejection, autoimmune diseases, cancer, and rare/infectious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. reports positive Phase 3 RESILIENT study results for Tonmya™ in fibromyalgia, positioning it for NDA submission in 2024. Commercial planning underway for potential U.S. launch. Financial results for Q4 and full year 2023 revealed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announces a registered direct offering of 14,666,666 shares of common stock and warrants with existing investors, aiming to raise capital for future growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-43.1%
Tags
offering
News
Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announced that the FDA granted Rare Pediatric Disease Designation to TNX-2900, a proprietary magnesium-potentiated formulation of intranasal oxytocin, for the treatment of Prader-Willi syndrome in children and adolescents. This designation recognizes the significant unmet need for effective treatments for PWS, a genetic disorder causing life-threatening childhood obesity. The Company may receive a transferable Priority Review Voucher upon approval, potentially worth $100 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.2%
Tags
none
-
News
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announces ongoing Phase 2 studies of TNX-1900 and TNX-2900 for various disorders. The company presented a poster at the ACS Spring 2024 Meeting on novel oxytocin analogues for pain, eating disorders, and endocrine conditions. Intranasal oxytocin shows promise in reducing food intake and improving insulin sensitivity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.8%
Tags
none
-
News
Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya™ for the Management of Fibromyalgia
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announces the selection of two contract manufacturing organizations for the commercial launch of Tonmya™, a potential new first-line, centrally acting non-opioid analgesic for fibromyalgia. Positive Phase 3 study results show significant pain reduction and improvements in sleep quality, fatigue, and overall fibromyalgia symptoms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.11%
Tags
none
News
Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announces the transition to a fully integrated pharmaceutical company by April 1, 2024, following the acquisition of Zembrace SymTouch and Tosymra. The company will market these products through its subsidiary and prepare for the potential launch of Tonmya for fibromyalgia in 2025, pending FDA approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.14%
Tags
none
-
News
Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. reported positive results from the second Phase 3 trial of Tonmya™ for fibromyalgia management. The company plans to submit a New Drug Application (NDA) to the FDA in the second half of 2024. In Japan, China, and most European countries, cyclobenzaprine is considered a New Chemical Entity. Tonix CEO will present at the 2024 BIO-Europe Spring Convention in Barcelona, Spain.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.86%
Tags
none
-
News
Tonix Pharmaceuticals Reports Improvement in “Brain Fog,” in Fibromyalgia Patients Treated with Tonmya™ in RESILIENT, an NDA-Enabling Phase 3 Clinical Trial, at the 6th International Congress on Controversies in Fibromyalgia
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announced positive Phase 3 RESILIENT study results for Tonmya in fibromyalgia treatment, meeting primary and all secondary endpoints with significant improvements in pain reduction, sleep quality, fatigue, and cognitive dysfunction. NDA submission expected in the second half of 2024 following FDA meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.31%
Tags
clinical trial
News
Tonix Pharmaceuticals Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of Therapy
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announces positive results from TNX-102 SL therapy studies for PTSD and acute stress reaction. The company's research paper highlights the potential of bedtime TNX-102 SL treatment in improving PTSD severity and sleep quality in military-related PTSD cases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
none
Stock TNXP logo
Tonix Pharmaceuticals Holding Corp

Nasdaq:TNXP

TNXP Rankings

#5252 Ranked by Market Cap
#5322 Ranked by Stock Gains
N/A Ranked by Dividends

TNXP Stock Data

15.53M
84.49M
0.01%
19.85%
1.7%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Chatham

About TNXP

tonix is developing innovative pharmaceutical products to address major public health challenges. in addition to tonmya for ptsd, tonix is developing tnx-601 (tianeptine oxalate), a clinical candidate at pre-ind (investigational new drug) application stage, designed as a daytime treatment for ptsd and tnx-801, a live synthetic version of horsepox virus, at the pre-ind application stage, to be developed as a potential smallpox-preventing vaccine. further information about tonix can be found at www.tonixpharma.com.